Ronquest N, Paret K, Mladsi DM, Lee LJ. Exploring the value of country-specific cost-effectiveness models in early stages of drug development. Poster presented at the ISPOR Europe 2023; November 2023. Copenhagen, Denmark. [abstract] Value Health. 2023 Dec; 26(12 supplement):S94. doi: 10.1016/j.jval.2023.09.493
Paret K, Ronquest N, Droege M. Economic modeling considerations for rare neurodegenerative diseases of infancy and early childhood. Poster presented at the ISPOR Europe 2022; November 9, 2022. Vienna, Austria. [abstract] Value Health. 2022 Dec 1; 25(12):S171. doi: 10.1016/j.jval.2022.09.830
Ronquest N, Clinkscales M, Paret K. How are United States ICER'S evidence ratings determined?: A systematic review of ICER'S evidence ratings in evidence reports for new drugs in 2020 and 2021. Poster presented at the ISPOR Europe 2022; November 7, 2022. Vienna, Austria. [abstract] Value Health. 2022 Dec 1; 25(12):299-300. doi: 10.1016/j.jval.2022.09.1479
Petrillo J, Paret K, Sawant R, Koenig A, Wolowacz S, Ronquest N, Rickards H. Estimation of health state utilities in Huntington's disease: a targeted review. Poster presented at the HSG 2022 Annual Meeting; November 2022. Tampa, FL. [abstract] J Huntingtons Dis. 2022 Oct 31; 11(s1):S31. Previously presented at the European Huntington's Disease Network (EHDN) 2022 Plenary Meeting. doi: 10.3233/JHD-229005
Petrillo J, Paret K, Sawant R, Koenig A, Wolowacz S, Ronquest N, Rickards H. Estimation of health state utilities in Huntington's disease: a targeted review. Poster presented at the European Huntington's Disease Network (EHDN) 2022 Plenary Meeting; September 18, 2022. Bologna, Italy. [abstract] J Neurol Neurosurg Psychiatry. 2022 Sep 12; 93(suppl 1):A45-6. doi: 10.1136/jnnp-2022-ehdn.118
Herring W, Mladsi DM, Ronquest NA. AD valorem: Alzheimer's disease, atopic dermatitis, and challenges for value assessment in chronic conditions. Poster presented at the ISPOR 2022 Conference; May 17, 2022. Washington, DC. [abstract] Value Health. 2022 Jun; 25(6 S1).
Wheeler A, Ling W, Nadipelli V, Ronquest N, Aldridge A, Solem C, Peiper N, Learned S, Heidbreder C. Recovery from opioid use disorder post-monthly buprenorphine extended release treatment: 12-month longitudinal outcomes. Poster presented at the 2019 AMCP NEXUS; October 29, 2019. National Harbor, MD. [abstract] J Manag Care Spec Pharm. 2019 Oct; 25(10-a):S14. doi: 10.18553/jmcp.2019.25.10-a.s1
Ronquest NA, Gould IG, Barnett CL, Mladsi DM. A systematic review of ICER evaluations from 2008 to 2018: recent trends in evaluation process and lessons learned. Poster presented at the 2019 ISPOR 24th Annual International Meeting; May 21, 2019. New Orleans, LA. [abstract] Value Health. 2019 May; 22(2):S263-4.
Wollschlaeger BA, Ronquest NA, Montejano LB, Wilson TM, Nadipelli VR. Narcotic pain medication and other concomitant medication use before and after buprenorphine maintenance treatment initiation in patients with opioid dependence. Poster presented at the 2016 PAINWeek Conference; September 2016. Las Vegas, NV. [abstract] Postgrad Med. 2018 Aug; 128(Sup2):63-4. doi: 10.1080/00325481.2016.1224633
Sabar U, Rycroft C, Ronquest NA, Nadipelli VR, Wollschlaeger B, Akehurst R. Analysis of humanistic burden reveals a need for opioid use disorder (OUD) disease-specific HRQoL instruments. Poster presented at the 2017 ISPOR 22nd Annual International Meeting; May 2017. Boston, MA. [abstract] Value Health. 2017 May; 20(5):A300.
Sabar U, Rycroft C, Ronquest NA, Nadipelli VR, Wollschlaeger B, Akehurst R. The economic burden of opioid use disorder (OUD): results of a structured literature review. Poster presented at the 2017 ISPOR 22nd Annual International Meeting; May 2017. Boston, MA. [abstract] Value Health. 2017 May; 20(5):A298.
Elroy PW, Ronquest NA, Barnes A, Nadipelli VR, Akehurst R. Evaluating the effectiveness of treatments of opioid use disorder based on recovery outcomes: how to bridge the disconnect between clinical trial outcomes and recovery outcomes? Poster presented at the 2016 ISPOR 19th Annual European Congress; October 2016. Vienna, Austria. [abstract] Value Health. 2016 Nov; 19(7):A361.
Cranmer H, Ronquest NA, Barnes A, Nadipelli VR, Akehurst R. To what extent does the published economic analyses of treatments for opioid use disorder capture its chronic, relapsing nature and its impact on society? Poster presented at the 2016 ISPOR 19th Annual European Congress; November 2016. Vienna, Austria. [abstract] Value Health. 2016 Nov; 19(7):A373.
Cranmer H, Ronquest NA, Barnes A, Nadipelli VR, Akehurst R. Health-related quality of life in opioid use disorder measured by utilities: a systematic literature review. Poster presented at the 2016 ISPOR 19th Annual European Congress; November 2016. Vienna, Austria. [abstract] Value Health. 2016 Nov; 19(7):A387.
Wollschlaeger B, Montejano LB, Wilson TM, Ronquest N, Juneau PL, Nadipelli VR. Real-world evidence: buprenorphine adherence predictive of reduced risk of opioid relapse. Poster presented at the 2016 Academy of Managed Care Pharmacy Nexus; October 2016. National Harbor, MD. [abstract] J Manag Care Spec Pharm. 2016 Oct; 22(10-a):S43.
Montejano LB, Ronquest NA, Willson TM, Wollschlaeger BA, Cole AL, Nadipelli VR. How to measure 'opioid relapse' in real-world claims data. Poster presented at the 2016 ISPOR 21st Annual International Meeting; May 2016. Washington, DC. [abstract] Value Health. 2016 May; 19(3):A72.
Tkacz JMS, Brady B, Nadipelli VR, Volpicelli J, Ronquest NA. The association between buprenorphine medication assisted treatment adherence and healthcare service utilization and costs. Poster presented at the 2016 ISPOR 21st Annual International Meeting; May 2016. Washington, DC. [abstract] Value Health. 2016 May; 19(3):A187.
Ronquest N, Wollschlaeger B, Montejano L, Wilson T, Nadipelli V. Characteristics and treatment patterns of US medicaid patients with opioid use disorder. Poster presented at the 2016 International Conference on Opioids Conference; June 2016. Boston, MA. [abstract] J Opioid Manag. 2016 May; 12(3):227.
Brady B, Tkacz JMS, Nadipelli VR, Volpicelli J, Ronquest NA, Un H, Ruetsch C. Relapse in opioid use disorder: implications for healthcare utilization and costs. Poster presented at the 2016 ISPOR 21st Annual International Meeting; May 2016. Washington, DC. [abstract] Value Health. 2016 May; 19(3):A188.
Willson T, Montejano L, Wollschlaeger B, Ronquest N, Nadipelli V. Real-world dosing patterns among patients receiving buprenorphine for opioid dependence in the United States. Poster presented at the 2016 AMCP Managed Care & Specialty Pharmacy Annual Meeting; April 2016. San Francisco, CA. [abstract] J Manag Care Pharm. 2016 Apr; 22(4-a):S60.
Mladsi D, Ramamohan V, Ronquest N, Boklage SH. A cost-consequences analysis of inpatient tolvaptan compared with fluid restriction among SIADH patients with hyponatremia. Poster presented at the 2015 AMCP Nexus; October 26, 2015. Orlando, FL. [abstract] J Manag Care Pharm. 2015 Oct; 21(10-a):S33.
Ramamohan V, Mladsi D, Ronquest N, Boklage S. A cost-consequences analysis of inpatient tolvaptan compared with fluid restriction among CHF patients with hyponatremia. Poster presented at the 2015 AMCP Nexus; October 26, 2015. Orlando, FL. [abstract] J Manag Care Pharm. 2015 Oct; 21(10-a):S53.
Mladsi DM, Ronquest NA, Tannus G, Fonseca M, Saag K. Estimated cost effectiveness of lower-dose submicron diclofenac compared with traditional diclofenac in Brazil. Poster presented at the 2013 ISPOR 4th Latin America Conference; September 2013. Buenos Aires, Argentina. [abstract] Value Health. 2013 Sep; 16(7):PA717-8. doi: 10.1016/j.jval.2013.08.2226
Odom DM, Mladsi DM, Saag K, Ronquest NA, Wang J. Estimating the relationship between diclofenac drug dosage and risk of gastrointestinal toxicity: meta-regression based on a systematic literature review. Poster presented at the 2013 Digestive Disease Week; May 2013. Orlando, FL. [abstract] Gastroenterology. 2013 May; 144(5 Suppl 1):S-673. doi: 10.1016/S0016-5085(13)62496-8
Herring WL, Mladsi DM, Miles L, Ronquest N. A novel approach to ranking parameter uncertainty in one-way sensitivity analysis: what tornado diagrams are missing. Poster presented at the 2013 ISPOR 18th Annual International Meeting; May 1, 2013. New Orleans, LA. [abstract] Value Health. 2013 May; 16(3):A20.
Ronquest N, Mladsi D, Hopley C, Edgell E. The economic value of an innovative knee implant system for total knee arthroplasty. Poster presented at the 2013 ISPOR 18th Annual International Meeting; May 6, 2013. New Orleans, LA. [abstract] Value Health. 2013 May; 16(3):A225.
Mladsi DM, Graham JB, Ronquest NA. Trade-off analysis: an extension of threshold pricing analysis. Poster presented at the 2012 ISPOR 17th Annual International Meeting; June 7, 2012. Washington, DC. [abstract] Value Health. 2012 Jun; 15(4):A169.
Mladsi D, Earnshaw S, Ronquest NA, Keith M. The threshold pricing model: not just another cost-effectiveness model. Poster presented at the 2010 ISPOR 13th Annual European Congress; November 15, 2010. Prague, Czech Republic. [abstract] Value Health. 2010 Nov; 13(7):A332.
Mladsi D, Earnshaw S, Akashi-Ronquest N, Keith M. Proposed methods for conducting sensitivity analyses on threshold-derived estimates of value-based price and product profiles of early stage drugs. Poster presented at the 2010 ISPOR 13th Annual European Congress; November 15, 2010. Prague, Czech Republic. [abstract] Value Health. 2010 Nov; 13(7):A333.